Table 1 Demographic and clinical features week 12 comparison of responders vs non-responders
Responders, N = 15 (38.5%) | Non-responders, N = 24 (61.5%) | t or χ 2 (df = 1) | P value | |
|---|---|---|---|---|
Age, mean(s) | 41.33 ± 9.5 | 50.7 ± 0.2 | 2.865 | NS |
General features | F = 9; M = 6 | F = 1; M = 23 | -0.152 | NS |
Weight (in kg) | 68.4 ± 15.71 | 68.29 ± 12.11 | 36 | NS |
Clinical features (%) | ||||
HAM-D total score | 4.27 ± 3.15 | 13.71 ± 2.53 | 10.320 | 0.001 |
HAM-A total score | 6.60 ± 3.58 | 12.83 ± 4.76 | 4.351 | 0.001 |
YMRS total score | 1.93 ± 1.62 | 3.21 ± 1.16 | 2.394 | 0.022 |
ASEX total score | 18.20 ± 5.69 | 18.58 ± 4.87 | 0.224 | NS |
Side effects profile (%) | ||||
Diarrhea | 0 | 4 (10.25%) | 2.786 | NS |
Tremors | 0 | 2 (5.12%) | 1.318 | NS |
Poor coordination | 0 | 2 (5.12%) | 1.318 | NS |
Dizziness | 0 | 4 (10.25%) | 2.786 | NS |
Blurred vision | 3 (7.7%) | 6 (15.4%) | 0.130 | NS |
Ringing in ears | 4 (10.25%) | 0 | 7.131 | 0.008 |
Difficult urination | 4 (10.25%) | 2 (5.12%) | 2.383 | NS |
Painful urination | 0 | 2 (5.12%) | 1.318 | NS |
Pollachiuria | 1 (2.6%) | 2 (5.12%) | 0.036 | NS |
Menstrual irregularity | 0 | 0 | - | - |
Insomnia | 11 (28.2%) | 18 (46.15%) | 0.013 | NS |
Hypersomnia | 0 | 4 (10.25%) | 2.786 | NS |
Loss of libido | 4 (10.25%) | 12 (30.77%) | 2.077 | NS |
Anorgasmy | 4 (10.25%) | 18 (46.15%) | 8.770 | 0.003 |
Erectile dysfunction | 0 | 0 | - | - |
Poor concentration | 1 (2.6%) | 16 (41%) | 13.514 | 0.001 |
General malaise | 0 | 14 (35.9%) | 13.650 | 0.001 |
Reduced energy | 3 (7.7%) | 12 (30.77%) | 3.510 | NS |
Hyperphagia | 2 (5.12%) | 4 (10.25%) | 0.079 | NS |